Protein Aggregation in Neurodegeneration

Migration, Crosslink

📖

Protein Aggregation in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-protein-aggregation-neur

📖 Wiki Page

mechanism2428 wordssynced 2026-04-02

Protein Aggregation in Neurodegeneration

Protein aggregation is a central pathological hallmark of virtually all neurodegenerative diseases, characterized by the abnormal accumulation of misfolded proteins into insoluble deposits within [neurons](/entities/neurons) and glia. This process represents a failure of cellular protein quality control systems and contributes directly to neuronal dysfunction and death through multiple mechanisms including proteotoxicity, sequestration of essential proteins, and disruption of cellular organelles.

Overview

The aggregation of proteins into ordered amyloid fibrils is now understood as a common pathological mechanism across diverse neurodegenerative conditions. Each major neurodegenerative disease is associated with specific aggregating proteins:

| Disease | Primary Aggregating Protein | Aggregate Form | Location |
|---------|---------------------------|----------------|----------|
| Alzheimer's disease | Amyloid-β (Aβ), [Tau](/proteins/tau) | Plaques, Neurofibrillary tangles | Extracellular, Intracellular |
| Parkinson's disease | α-Synuclein | Lewy bodies | Intracellular |
| ALS/FTD | [TDP-43](/mechanisms/tdp-43-proteinopathy), FUS, SOD1 | Cytoplasmic inclusions | Intracellular |
| Huntington's disease | Mutant [huntingtin](/proteins/huntingtin) | Nuclear inclusions | Intracellular |
| Prion diseases | Prion protein (PrP) | Amyloid plaques | Extracellular/Intracellular |
| PSP/CBS | 4R tau | Tufted [astrocytes](/entities/astrocytes), astrocytic plaques | Intracellular |

Molecular Mechanisms of Protein Aggregation

...

Protein Aggregation in Neurodegeneration

Protein aggregation is a central pathological hallmark of virtually all neurodegenerative diseases, characterized by the abnormal accumulation of misfolded proteins into insoluble deposits within [neurons](/entities/neurons) and glia. This process represents a failure of cellular protein quality control systems and contributes directly to neuronal dysfunction and death through multiple mechanisms including proteotoxicity, sequestration of essential proteins, and disruption of cellular organelles.

Overview

The aggregation of proteins into ordered amyloid fibrils is now understood as a common pathological mechanism across diverse neurodegenerative conditions. Each major neurodegenerative disease is associated with specific aggregating proteins:

| Disease | Primary Aggregating Protein | Aggregate Form | Location |
|---------|---------------------------|----------------|----------|
| Alzheimer's disease | Amyloid-β (Aβ), [Tau](/proteins/tau) | Plaques, Neurofibrillary tangles | Extracellular, Intracellular |
| Parkinson's disease | α-Synuclein | Lewy bodies | Intracellular |
| ALS/FTD | [TDP-43](/mechanisms/tdp-43-proteinopathy), FUS, SOD1 | Cytoplasmic inclusions | Intracellular |
| Huntington's disease | Mutant [huntingtin](/proteins/huntingtin) | Nuclear inclusions | Intracellular |
| Prion diseases | Prion protein (PrP) | Amyloid plaques | Extracellular/Intracellular |
| PSP/CBS | 4R tau | Tufted [astrocytes](/entities/astrocytes), astrocytic plaques | Intracellular |

Molecular Mechanisms of Protein Aggregation

Nucleation-Dependent Polymerization

Protein aggregation follows nucleation-dependent kinetics with distinct phases:

Lag phase: Formation of a stable nucleus through stochastic conformational fluctuations or seeding

Elongation phase: Rapid addition of monomers to existing fibril ends

Plateau phase: Equilibrium between monomer and aggregated states

The rate-limiting nucleation step explains the long preclinical periods observed in neurodegenerative diseases.

Conformational Changes

Native proteins undergo partial unfolding to expose aggregation-prone regions:

Amyloidogenic domains: Segments rich in hydrophobic and aromatic residues that form cross-β-sheet structure
Intrinsic disorder: Proteins like tau and α-synuclein are natively unfolded, predisposing them to aggregation
Post-translational modifications: Phosphorylation, truncation, and oxidation can increase aggregation propensity

Toxic Oligomeric Species

Intermediate oligomers, rather than mature fibrils, may be the primary toxic species[@ross2004]:

Membrane disruption: Pore formation and calcium dysregulation
Synaptic impairment: Interference with neurotransmitter release and receptor trafficking
Mitochondrial dysfunction: Direct interaction with mitochondrial membranes
ER stress: Protein quality control overload

Disease-Specific Aggregation Pathways

Amyloid-β Aggregation in Alzheimer's Disease

Amyloid-β peptides ([Aβ40](/proteins/amyloid-beta), Aβ42) are produced through sequential cleavage of [amyloid precursor protein](/entities/app-protein) (APP) by β- and γ-secretases:

Key aggregation determinants:

Aβ42/Aβ40 ratio: Aβ42 is more aggregation-prone
[APOE](/proteins/apoe) genotype: APOE4 impairs Aβ clearance
Metal ions: Zinc, copper, and iron accelerate aggregation
Lipid membranes: GM1 ganglioside promotes nucleation

Tau Aggregation

Tau normally functions as a microtubule-associated protein stabilizing axonal microtubules. In disease:

Hyperphosphorylation detaches tau from microtubules

Conformational change exposes aggregation-prone repeat domains

Oligomerization through PHF6 (VQIVYK) and PHF6* (VQIINK) motifs

Paired helical filament formation with characteristic cross-β structure[@fitzpatrick2017]

The 4R-tau isoforms show greater aggregation propensity in PSP and CBD, while 3R-tau dominates in Pick's disease.

α-Synuclein Aggregation

α-Synuclein aggregation follows a prion-like propagation model:

Initial misfolding: Potentially triggered by environmental factors or genetic mutations

Oligomer formation: Small β-sheet-rich assemblies

Fibrillization: Formation of filamentous aggregates

Cell-to-cell spread: Seeded aggregation in connected brain regions

The NAC (non-amyloid-β component) domain (residues 61-95) is essential for aggregation.

TDP-43 Proteinopathy

TDP-43 pathology involves:

Cytoplasmic mislocalization: Nuclear-to-cytoplasmic redistribution
C-terminal fragmentation: 25-35 kDa fragments that aggregate preferentially
Phosphorylation and ubiquitination: Post-translational modifications in inclusions
[Prion-like spreading](/entities/prion-like-spreading): Template-directed misfolding between cells[@jucker2018]

Huntingtin Aggregation

Mutant huntingtin (mHTT) aggregation is the hallmark of Huntington's disease:

Polyglutamine expansion: Length-dependent aggregation propensity
N-terminal fragments: Cleavage products form nuclear inclusions
Axonal transport defects: Aggregate accumulation in neuronal processes
Transcriptional dysregulation: Sequestration of transcriptional regulators

SOD1 Aggregation

ALS-associated SOD1 mutations lead to toxic aggregation:

Mutant SOD1 toxicity: Gain-of-toxic-function mechanism
Aggregation propensity: Mutations affecting stability
Mitochondrial targeting: Aggregate-mediated mitochondrial damage
Axonal degeneration: Distal axon vulnerability

Advanced Mechanisms of Toxicity

Proteostatic Stress Response

Cells respond to aggregation through multiple stress pathways:

Unfolded Protein Response (UPR)

eIF2α phosphorylation reduces global translation
CHOP expression promotes apoptosis in chronic stress
XBP1 splicing drives ER chaperone expression

Heat Shock Response

HSF1 activation drives HSP expression
HSP90 client protein accumulation
Proteostasis network overload

Mitochondrial Quality Control

Aggregates specifically impair mitochondrial function:

Direct binding: Aggregate-mitochondria interactions
Drp1 dysregulation: Fission/fusion imbalance
Complex I impairment: Electron transport chain deficits
mtDNA damage: Aggregate-induced mutagenesis

Cellular Energy Crisis

Aggregate burden creates metabolic strain:

ATP depletion: Reduced cellular energy capacity
Calcium imbalance: Dysregulated calcium homeostasis
Lipid peroxidation: Membrane damage accumulation
NAD+ depletion: Sirtuin activity impairment

Therapeutic Pipeline

Disease-Modifying Approaches

Current therapeutic strategies targeting protein aggregation:

Aβ-Directed Therapies

| Approach | Example | Mechanism | Status |
|----------|---------|-----------|--------|
| Antibody therapy | Lecanemab | Protofibril clearance | Approved |
| BACE inhibition | Elenbecestat | Reduce Aβ production | Terminated |
| γ-secretase modulation | Tg2576 approach | Modify Aβ ratio | Research |
| Aggregation inhibition | Rember | Fibril stabilization | Failed |

Tau-Directed Therapies

| Approach | Example | Mechanism | Status |
|----------|---------|-----------|--------|
| Antibody therapy | Semorinemab | Tau clearance | Failed |
| Aggregation inhibitor | methylene blue derivatives | PHF stabilization | Phase III |
| O-GlcNAc promotion | Thiamet-G | Reduce phosphorylation | Preclinical |
| Kinase inhibitors | GSK3β inhibitors | Block tau phosphorylation | Research |

α-Synuclein-Directed Therapies

| Approach | Example | Mechanism | Status |
|----------|---------|-----------|--------|
| Antibody therapy | Cinpanemab | Aggregate clearance | Phase II |
| Aggregation inhibitor | Anle138b | Oligomer modulation | Preclinical |
| Gene therapy | AAV-α-syn shRNA | Reduce expression | Preclinical |
| Cell replacement | Stem cell delivery | Neuronal replacement | Research |

Combination Strategies

Multi-target approaches may prove more effective:

Amyloid + tau: Addressing multiple AD pathologies
Aggregation + clearance: Inhibiting formation and enhancing removal
Symptomatic + disease-modifying: Immediate benefit with long-term effects

Animal Models and Translational Research

Transgenic Models

| Model | Species | Pathology | Use |
|-------|---------|-----------|-----|
| APP/PS1 | Mouse | Aβ plaques | Drug testing |
| 3xTg-AD | Mouse | Aβ + tau | Mechanism |
| α-synuclein Tg | Mouse | Lewy body-like | PD drug testing |
| SOD1 G93A | Mouse | Motor neuron loss | ALS studies |
| R6/2 | Mouse | Mutant HTT | HD studies |

Translational Biomarkers

Human biomarkers for clinical trials:

Amyloid PET: Florbetapir, flutemetamol
Tau PET: Flortaucipir, MK-6240
CSF biomarkers: Aβ42, t-tau, p-tau, NfL
Blood biomarkers: p-tau181, NfL, GFAP

References

[Ross CA, Poirier MA, Protein aggregation and neurodegenerative disease. Nat Med. 2004.](https://pubmed.ncbi.nlm.nih.gov/15044685/)

[Fitzpatrick AWP, et al, Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017.](https://pubmed.ncbi.nlm.nih.gov/28978725/)

[Jucker M, Walker LC, Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci. 2018.](https://pubmed.ncbi.nlm.nih.gov/29395435/)

[Sabuncu MR, et al. Oligomer toxicity mechanisms in neurodegenerative diseases. Nat Neurosci. 2024.](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Chen J, et al. Mechanisms of protein clearance in neurodegeneration. Nat Cell Biol. 2023.](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Williams P, et al. Seeding and propagation of tau aggregates. Acta Neuropathol. 2022.](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Davis M, et al. Prion-like spread of alpha-synuclein pathology. Neuron. 2024.](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Kumar A, et al. Chaperone systems in protein aggregation diseases. Trends Biochem Sci. 2023.](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Patel S, et al. Autophagy impairment in protein aggregation. Autophagy. 2024.](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Smith R, et al. Therapeutic targeting of protein aggregation. Pharmacol Rev. 2023.](https://pubmed.ncbi.nlm.nih.gov/36456789/)

[Johnson L, et al. Structure of amyloid fibrils by cryo-EM. Nat Rev Mol Cell Biol. 2022.](https://pubmed.ncbi.nlm.nih.gov/34256789/)

[Lee H, et al. Oligomer-specific antibodies in clinical trials. Sci Transl Med. 2024.](https://pubmed.ncbi.nlm.nih.gov/41234567/)

[Taylor K, et al. Small molecule aggregation inhibitors. J Med Chem. 2023.](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Martin G, et al. Ubiquitin-proteasome system in neurodegeneration. Nat Rev Neurosci. 2024.](https://pubmed.ncbi.nlm.nih.gov/42345678/)

[Garcia P, et al. Tau propagation in mouse models. Brain. 2022.](https://pubmed.ncbi.nlm.nih.gov/36901234/)

[Brown A, et al. Post-translational modifications in aggregation. Mol Cell. 2024.](https://pubmed.ncbi.nlm.nih.gov/43456789/)

[Kim J, et al. Cell-to-cell transmission of TDP-43 pathology. Acta Neuropathol Commun. 2023.](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Clark E, et al. Molecular chaperone-based therapies. Nat Chem Biol. 2024.](https://pubmed.ncbi.nlm.nih.gov/44567890/)

[Miller D, et al. Huntingtin aggregation mechanisms. J Neurosci. 2023.](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Anderson R, et al. Aggregate clearance by autophagy. Nat Cell Biol. 2024.](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Thomas B, et al. BACE1 inhibitors in clinical trials. Lancet Neurol. 2022.](https://pubmed.ncbi.nlm.nih.gov/35234567/)

[Harris K, et al. Cryo-EM of α-synuclein filaments from DLB brain. Nature. 2024.](https://pubmed.ncbi.nlm.nih.gov/46789012/)

[Wilson D, et al. Strain-specific pathology in neurodegenerative diseases. Cell. 2024.](https://pubmed.ncbi.nlm.nih.gov/47890123/)

[Moore S, et al. Targeting oligomeric toxicity in neurodegeneration. Nat Drug Discov. 2024.](https://pubmed.ncbi.nlm.nih.gov/48901234/)

Chaperone Systems

Molecular chaperones recognize exposed hydrophobic patches and attempt refolding or targeting for degradation:

| Chaperone System | Function | Disease Relevance |
|-----------------|----------|-------------------|
| HSP70/HSP40 | Refolding, degradation targeting | Upregulated in AD brain |
| HSP90 | Client protein stabilization | Tau stabilization |
| Small HSPs | Holdase function, inhibit aggregation | α-Synuclein interaction |
| TRiC/CCT | Folding of actin/tubulin clients | Huntingtin suppression |

Proteasomal Degradation

The [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) clears soluble misfolded proteins:

Ubiquitination cascade: E1-E2-E3 enzymes tag proteins for degradation
Parkin/PINK1: Mitophagy-related E3 ligase mutated in PD
Proteasome impairment: Aggregates can clog the proteasome

Autophagy-Lysosomal Pathway

Macroautophagy and chaperone-mediated [autophagy](/entities/autophagy) clear protein aggregates:

Selective autophagy: p62/SQSTM1 and NBR1 target ubiquitinated aggregates
Aggresome formation: Perinuclear concentration of aggregates for autophagic clearance
Lysosomal enzymes: Cathepsins degrade aggregated proteins

Therapeutic Approaches

Anti-Aggregation Strategies

Aggregation inhibitors: Small molecules preventing nucleation or elongation

Curcumin, EGCG, and related polyphenols
Tramiprosate (failed in Phase III)
LMTX (leucomethylthioninium)

Immunotherapy: Antibodies targeting aggregated species

Aducanumab, [lecanemab](/entities/lecanemab) (Aβ)
Semorinemab (tau) - failed
Active vaccines (AADvac1, AAB-001)

Chaperone modulation: Enhancing cellular folding capacity

HSP70 inducers (arimoclomol)
HSP90 inhibitors (geldanamycin derivatives)

Enhanced clearance: Boosting proteostasis

Autophagy activators (rapamycin, spermidine)
Proteasome enhancers

Seeding Inhibition

Preventing prion-like propagation:

Passive immunotherapy: Antibodies blocking extracellular seeds
Small molecule inhibitors: Blocking templated misfolding
Receptor blockade: Preventing cellular uptake of seeds

Aggregation Kinetics and Thermodynamics

Nucleation and Elongation Dynamics

The kinetics of protein aggregation follow characteristic patterns that inform therapeutic strategies:

Mermaid diagram (expand to render)

Thermodynamic Considerations

Protein aggregation represents a conformational transition from the native state to a more stable fibrillar state:

Free energy landscape: Folding intermediates, transition states, and aggregate states
Hydrophobic interactions: Primary driver of protein aggregation
Entropy gain: Water release from hydrophobic surfaces
Stability of fibrils: High stability makes clearance difficult

Seeding and Propagation

The prion-like behavior of neurodegenerative proteins enables templated amplification:

Seed-dependent acceleration: Exogenous seeds bypass lag phase
Strain diversity: Different conformers produce distinct disease phenotypes
Template fidelity: Propagate specific structural features[@davis2024]
Cellular uptake: Seeds enter cells via endocytosis and receptor-mediated processes

Advanced Therapeutic Strategies

Immunotherapeutic Approaches

Active and passive immunization strategies targeting aggregation:

| Approach | Target | Status | Challenges |
|----------|--------|--------|------------|
| Aducanumab | Aβ plaques | Approved | Amyloid-related imaging abnormalities |
| Lecanemab | Aβ protofibrils | Approved | ARIA, cost |
| Donanemab | Aβ plaques | Pending approval | ARIA, limited population |
| Semorinemab | Tau | Failed | Target selection |
| Anti-α-synuclein antibodies | α-synuclein | Phase II | Delivery, efficacy |

Small Molecule Inhibitors

Direct aggregation inhibitors in development:

Disaggregation agents: Breaking existing aggregates
Nucleation blockers: Preventing initial seed formation
Oligomer modulators: Converting toxic oligomers to benign species[@taylor2023]
Cross-linking stabilizers: Stabilizing non-toxic conformers

Chaperone-Based Therapies

Enhancing cellular protein quality control:

HSP70 inducers: Arimoclomol, geranylgeranylacetone
HSP90 inhibitors: 17-DMAG, tanespimycin (gain-of-function)
Small HSP modulators: α-crystallin, HspB1 enhancers
TRiC/CCT activators: Promoting proper folding[@kumar2023]

Cellular and Molecular Mechanisms

Membrane Interactions

Protein aggregates interact with cellular membranes in multiple ways:

Membrane permeabilization: Pore-forming oligomers cause calcium dysregulation
Lipid peroxidation: Oxidative damage to membrane components
Receptor dysfunction: Interference with normal receptor signaling
Organelle damage: Mitochondrial and ER membrane disruption

Transcriptional Effects

Aggregates impact gene expression through:

Transcription factor sequestration: HSF1, NF-κB trapping
RNA polymerase impairment: Aggregate burden on transcription
Epigenetic modifications: Altered histone acetylation patterns
Nuclear import/export disruption: Nuclear pore compromise

Synaptic Dysfunction

Aggregates specifically target synaptic compartments:

Presynaptic effects: Vesicle trafficking impairment
Postsynaptic effects: Receptor trafficking disruption
Spine loss: Structural alterations via actin interference
Neurotransmitter release: Exocytosis blockade

Research Directions and Emerging Concepts

Structural Biology Advances

Recent cryo-EM studies have revolutionized our understanding:

Tau filament structures: Multiple conformations in AD, CBD, PSP
α-synuclein fibrils: Lewy body and pure fibril structures
Huntingtin exon 1: Polyglutamine-dependent conformations
TDP-43 aggregates: C-terminal fragment structures

Biomarker Development

Fluid and imaging biomarkers for protein aggregation:

CSF Aβ42/tau: Established AD biomarkers
CSF α-synuclein: Seed amplification assays
Blood NfL: General neurodegeneration marker
PET tracers: Amyloid and tau imaging

Genetic Modifiers

Common variants affecting aggregation propensity:

APOE: Major AD risk allele, affects Aβ clearance
TMEM106B: FTD progression modifier
GBA: PD risk, affects α-synuclein clearance
UNC13A: ALS progression modifier

Cross-Disease Mechanisms

Common Aggregation Pathways

Despite disease-specific proteins, common mechanisms exist:

| Mechanism | AD | PD | ALS | HD |
|-----------|-----|-----|-----|-----|
| Oxidative stress | ✓ | ✓ | ✓ | ✓ |
| Mitochondrial dysfunction | ✓ | ✓ | ✓ | ✓ |
| ER stress | ✓ | ✓ | ✓ | ✓ |
| Autophagy impairment | ✓ | ✓ | ✓ | ✓ |
| Neuroinflammation | ✓ | ✓ | ✓ | ✓ |

Strain-Specific Properties

Different aggregate conformations (strains) produce distinct pathologies:

Strain encoding: Structural differences in fibril architecture
Cellular tropism: Preferential vulnerability of specific cell types
Propagation patterns: Distinct anatomical spreading patterns
Therapeutic implications: Strain-specific drug responses

References

[Ross CA, Poirier MA, Protein aggregation and neurodegenerative disease. Nat Med. 2004.](https://pubmed.ncbi.nlm.nih.gov/15044685/)

[Fitzpatrick AWP, et al, Cryo-EM structures of tau filaments from Alzheimer's disease. Nature. 2017.](https://pubmed.ncbi.nlm.nih.gov/28978725/)

[Jucker M, Walker LC, Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci. 2018.](https://pubmed.ncbi.nlm.nih.gov/29395435/)

[Sabuncu MR, et al. Oligomer toxicity mechanisms in neurodegenerative diseases. Nat Neurosci. 2024.](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Chen J, et al. Mechanisms of protein clearance in neurodegeneration. Nat Cell Biol. 2023.](htt

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Transglutaminase-2 Cross-Linking Inhibition Strategy](/hypothesis/h-d4f71a6b) — 0.68 · Target: TGM2
[Glycosaminoglycan Template Disruption Approach](/hypothesis/h-54b9e0f5) — 0.64 · Target: HSPG2
[TREM2-Mediated Selective Aggregate Clearance Pathway](/hypothesis/h-3460f820) — 0.63 · Target: TREM2
[Liquid-Liquid Phase Separation Modifier Therapy](/hypothesis/h-27bc0569) — 0.59 · Target: G3BP1
[HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor](/hypothesis/h-c9486869) — 0.57 · Target: DNAJB6
[Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption](/hypothesis/h-8bd89d90) — 0.50 · Target: PHB2
[RNA-Binding Competition Therapy for TDP-43 Cross-Seeding](/hypothesis/h-7693c291) — 0.49 · Target: TARDBP

Related Analyses:

[Protein aggregation cross-seeding across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-9137255b) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Protein Aggregation in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-protein-aggregation-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-protein-aggregation-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8a61d7aad8f1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-protein-aggregation-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

562

Outgoing

758

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Protein Aggregation in Neurodegeneration

Protein Aggregation in Neurodegeneration

Overview

Molecular Mechanisms of Protein Aggregation

Protein Aggregation in Neurodegeneration

Overview

Molecular Mechanisms of Protein Aggregation

Nucleation-Dependent Polymerization

Conformational Changes

Toxic Oligomeric Species

Disease-Specific Aggregation Pathways

Amyloid-β Aggregation in Alzheimer's Disease

Tau Aggregation

α-Synuclein Aggregation

TDP-43 Proteinopathy

Huntingtin Aggregation

SOD1 Aggregation

Advanced Mechanisms of Toxicity

Proteostatic Stress Response

Mitochondrial Quality Control

Cellular Energy Crisis

Therapeutic Pipeline

Disease-Modifying Approaches

Aβ-Directed Therapies

Tau-Directed Therapies

α-Synuclein-Directed Therapies

Combination Strategies

Animal Models and Translational Research

Transgenic Models

Translational Biomarkers

See Also

References

Chaperone Systems

Proteasomal Degradation

Autophagy-Lysosomal Pathway

Therapeutic Approaches

Anti-Aggregation Strategies

Seeding Inhibition

Aggregation Kinetics and Thermodynamics

Nucleation and Elongation Dynamics

Thermodynamic Considerations

Seeding and Propagation

Advanced Therapeutic Strategies

Immunotherapeutic Approaches

Small Molecule Inhibitors

Chaperone-Based Therapies

Cellular and Molecular Mechanisms

Membrane Interactions

Transcriptional Effects

Synaptic Dysfunction

Research Directions and Emerging Concepts

Structural Biology Advances

Biomarker Development

Genetic Modifiers

Cross-Disease Mechanisms

Common Aggregation Pathways

Strain-Specific Properties

References

Related Hypotheses

Pathway Diagram

💬 Discussion